Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

1747 - Hormonal therapy for epithelial ovarian cancer: a systematic review and meta-analysis of phase II studies


08 Oct 2016


Poster Display


Laura Paleari


Annals of Oncology (2016) 27 (6): 296-312. 10.1093/annonc/mdw374


L. Paleari1, N. Provinciali2, M. Puntoni3, C. Defferrari2, M. Di Luca4, F. Gorlero4, A. Decensi2

Author affiliations

  • 1 Medical Oncology, Ospedali Galliera, 16128 - Genova/IT
  • 2 Medical Oncology, Ospedali Galliera, 16132 - Genova/IT
  • 3 Clinical Trial And Biostatistical Unit, Scientific Direction, Ospedali Galliera, 16128 - Genova/IT
  • 4 Division Of Gynecology And Obstetrics, Ospedali Galliera, 16128 - Genova/IT


Abstract 1747


Endocrine therapy is a common clinical practice in epithelial ovarian cancer (EOC) and hormonal receptors have been associated with response and survival in recent studies. However, the degree of activity of endocrine therapy overall and by specific agents remains unclear.


Objective response rates (ORR) from phase II trials of different hormonal manipulations in EOC patients were meta-analyzed. Pooled estimates (PES) from random effect models were calculated according to type of intervention, ER/PgR status, tamoxifen dose, year of study and platinum resistance. Two randomized trials were excluded from analysis given their low number.


The analyses encompassed a total of 35 phase II trials including 1.690 patients. Overall, we obtained a PES = 0.37 [95%CI, 0.28-0.46] with any endocrine treatment. By specific agent class, PES was = 0.31 [95%CI, 0.23-0.39] for aromatase inhibitors, 0.40 [95%CI, 0.21-0.58] for tamoxifen, 0.41 [95%CI, 0.23-0.59] for estro-progestins, 0.39 [95%CI, 0.25-0.52] for tamoxifen plus progestins, 0.30 [95%CI, 0.20-0.40] for progestins, 0.14 [95%CI, 0-0.58] for the anti-androgen flutamide, 0.50 [95%CI, 0.31-0.69] for tamoxifen plus goserelin, 0.52 [95%CI, 0.32-0.72] for the ER downregulator fulvestrant, even though the last three categories included only one study each. The PES was better in studies including patients with ER + ve or PgR + ve disease [PES= 0.43, 95%CI, 0.34-0.52] compared with hormone receptor -ve [PES= 0.17, 95%CI, 0.09-0.24] or mixed [PES= 0.31 95%CI, 0.17-0.46] disease. High tamoxifen doses (>20 mg/day) exhibited a worse PES= 0.36 [95%CI, 0.16-0.57] than the standard dose of 20 mg/day (PES = 0.50 [95%CI, 0.13-0.87]. A slightly better response was noted in platinum resistant [PES= 0.35, 95%CI, 0.19-0.50] vs platinum sensitive patients [PES= 0.43, 95%CI, 0.3-0.57]. There was no evidence for a response trend by year of study.


The activity of endocrine therapy in advanced EOC looks promising but has not adequately been evaluated in definitive clinical trials. Given the recent evidence for a prognostic value of hormone receptors in EOC, our findings support the implementation of randomized trials in hormone receptor positive EOC.

Clinical trial identification

Legal entity responsible for the study

E.O. Galliera


Italian Association for Cancer Research (AIRC)


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings